NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans.
about
The dopamine hypothesis of schizophrenia: version III--the final common pathwayOccupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaDevelopmental mechanisms in the prodrome to psychosisDrug models of schizophreniaNeurophysiological and neurochemical animal models of schizophrenia: focus on glutamateN-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Neuroimaging studies in schizophrenia: an overview of research from Asia.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Do the dissociative side effects of ketamine mediate its antidepressant effects?Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis.Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.Glutamate and dopamine in schizophrenia: an update for the 21st centurySubanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.How have developments in molecular imaging techniques furthered schizophrenia research?Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum.Ketamine impairs multiple cognitive domains in rhesus monkeys.Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine.The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.Attentional bias to incentive stimuli in frequent ketamine users.Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
P2860
Q22242827-A9DC0CA4-8718-472E-A7C6-7EEF38CA9BF2Q24630426-AC119517-B4BC-43B9-9C85-406F91013ECCQ24646206-B4C92A71-B449-4D69-B8EA-8E0008ED78F3Q27009237-329E7C3B-27F4-44D7-8D55-E695637A3557Q28084198-C3D3C634-F1F0-4F9F-B9BE-213DE51532EAQ30403302-9EDD3538-2C23-4010-A946-02AAD3722ED8Q30474021-94DDFEAC-B5CC-473B-B7B0-3858A973E22FQ30564474-9C2636A6-71C4-4772-A59A-2D4FEA888EDCQ30573043-9E351A69-387E-4288-9C10-076E20EB6DB8Q30685335-F14D59B0-0A53-4132-8C0B-2D7172E13971Q33787133-81F1B8A3-BA90-4C97-A4EB-EB93818F66C9Q34579973-222933DE-8A86-414E-8597-84B37C803573Q35158156-1478619A-E611-4AA3-B256-9A56907C11B8Q36252816-D2D88B58-C803-4DCC-AEF6-0D54D9C98CE6Q36860038-522CE344-026A-423E-BC59-F39B2A688106Q36860042-4C81EE28-0A4B-4044-B295-4F4FD1D47236Q36992322-9FA939AF-CCC8-416C-BDE8-827738BD27EBQ37309756-6AEC68A4-215D-4AB9-B10A-9DA4635A3BB4Q37352417-6E0B2CC9-3820-4A32-806C-8D94AC8C8728Q37629424-1271E706-817B-448F-A665-B41F7FD41969Q37829639-E0FA661E-D7C0-478D-B9D3-EA1814B82F4DQ40733200-B297B255-7FF0-45D8-AA8C-8027883BC925Q42124923-5FC859C4-E126-435B-997C-519586C06C27Q44510576-2569CEC7-4E97-41F7-9C7D-EF052A1A1F03Q44531006-47711540-FBEE-498C-907A-5F72F9EC2101Q46296210-C70BA3C6-BF99-4778-BC6C-B36DE89DA1C3Q46715544-0E0FF7A5-AD36-4AAA-82D0-ABCDCC74A288Q46821493-3CCFF6F6-8E12-43E5-BDF0-1967EE78B974Q47746221-0A7112B7-A1DF-43A9-A4AA-AD780D92D904Q55438088-310A1FCB-C6EA-4DF5-B6E7-D16418705CF5
P2860
NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
NMDA antagonist effects on str ...... tomography studies in humans.
@en
NMDA antagonist effects on str ...... tomography studies in humans.
@nl
type
label
NMDA antagonist effects on str ...... tomography studies in humans.
@en
NMDA antagonist effects on str ...... tomography studies in humans.
@nl
prefLabel
NMDA antagonist effects on str ...... tomography studies in humans.
@en
NMDA antagonist effects on str ...... tomography studies in humans.
@nl
P2093
P2860
P356
P1433
P1476
NMDA antagonist effects on str ...... tomography studies in humans.
@en
P2093
Dah-Ren Hwang
Diana Martinez
Lawrence S Kegeles
Lisa D Kochan
Marc Laruelle
Osama Mawlawi
R F Suckow
Ronald L Van Heertum
Yiyun Huang
P2860
P356
10.1002/SYN.10010
P577
2002-01-01T00:00:00Z